BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, Grimm EA. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res 2019;25:1650-63. [PMID: 30538110 DOI: 10.1158/1078-0432.CCR-18-1163] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 An Y, Yao J, Niu X. The Signaling Pathway of PGE2 and Its Regulatory Role in T Cell Differentiation. Mediators Inflamm 2021;2021:9087816. [PMID: 34867083 DOI: 10.1155/2021/9087816] [Reference Citation Analysis]
2 Pu D, Yin L, Huang L, Qin C, Zhou Y, Wu Q, Li Y, Zhou Q, Li L. Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer. Front Oncol 2021;11:637504. [PMID: 33718229 DOI: 10.3389/fonc.2021.637504] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
3 Motofei IG. Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity. Expert Opin Drug Saf 2021;:1-14. [PMID: 34937484 DOI: 10.1080/14740338.2022.2020243] [Reference Citation Analysis]
4 Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov 2021;11:1368-97. [PMID: 33811048 DOI: 10.1158/2159-8290.CD-20-1209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Jiang X, Renkema H, Smeitink J, Beyrath J. Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth. PLoS One 2021;16:e0254315. [PMID: 34242345 DOI: 10.1371/journal.pone.0254315] [Reference Citation Analysis]
6 Fultang N, Li X, Li T, Chen YH. Myeloid-Derived Suppressor Cell Differentiation in Cancer: Transcriptional Regulators and Enhanceosome-Mediated Mechanisms. Front Immunol 2020;11:619253. [PMID: 33519825 DOI: 10.3389/fimmu.2020.619253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Nikolos F, Hayashi K, Hoi XP, Alonzo ME, Mo Q, Kasabyan A, Furuya H, Trepel J, Di Vizio D, Guarnerio J, Theodorescu D, Rosser C, Apolo A, Galsky M, Chan KS. Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nat Commun 2022;13:1487. [PMID: 35347124 DOI: 10.1038/s41467-022-29026-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A, Proto C, Galli G, Marra A, Apollonio G, Porcu L, de Braud F, Lo Russo G, Ferrara R, Garassino MC. Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. Cancers (Basel) 2019;12:E67. [PMID: 31881699 DOI: 10.3390/cancers12010067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
9 Cruz ALS, Barreto EA, Fazolini NPB, Viola JPB, Bozza PT. Lipid droplets: platforms with multiple functions in cancer hallmarks. Cell Death Dis. 2020;11:105. [PMID: 32029741 DOI: 10.1038/s41419-020-2297-3] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 33.0] [Reference Citation Analysis]
10 Terzuoli E, Bellan C, Aversa S, Ciccone V, Morbidelli L, Giachetti A, Donnini S, Ziche M. ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output. Cancers (Basel) 2019;11:E1963. [PMID: 31817719 DOI: 10.3390/cancers11121963] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
11 Ercolano G, De Cicco P, Rubino V, Terrazzano G, Ruggiero G, Carriero R, Kunderfranco P, Ianaro A. Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment. Front Pharmacol 2019;10:1456. [PMID: 31920649 DOI: 10.3389/fphar.2019.01456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Haase-Kohn C, Laube M, Donat CK, Belter B, Pietzsch J. CRISPR/Cas9 Mediated Knockout of Cyclooxygenase-2 Gene Inhibits Invasiveness in A2058 Melanoma Cells. Cells 2022;11:749. [PMID: 35203404 DOI: 10.3390/cells11040749] [Reference Citation Analysis]
13 Bayless S, Travers JB, Sahu RP, Rohan CA. Inhibition of photodynamic therapy induced-immunosuppression with aminolevulinic acid leads to enhanced outcomes of tumors and pre-cancerous lesions. Oncol Lett 2021;22:664. [PMID: 34386086 DOI: 10.3892/ol.2021.12925] [Reference Citation Analysis]
14 Pellerin L, Carrié L, Dufau C, Nieto L, Ségui B, Levade T, Riond J, Andrieu-Abadie N. Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives. Cancers (Basel) 2020;12:E3147. [PMID: 33121001 DOI: 10.3390/cancers12113147] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Markosyan N, Smyth EM, Patrignani P, Ricciotti E. Editorial: Eicosanoids in Cancer. Front Pharmacol 2021;12:765214. [PMID: 34566667 DOI: 10.3389/fphar.2021.765214] [Reference Citation Analysis]
16 Sheng Y, Wen L, Zheng X, Li M, Wang D, Chen S, Li R, Tang L, Zhou F. CYP2S1 might regulate proliferation and immune response of keratinocyte in psoriasis. Epigenetics 2021;16:618-28. [PMID: 32924783 DOI: 10.1080/15592294.2020.1814486] [Reference Citation Analysis]
17 Song M, Xia W, Tao Z, Zhu B, Zhang W, Liu C, Chen S. Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy. Drug Deliv 2021;28:594-606. [PMID: 33729072 DOI: 10.1080/10717544.2021.1898703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
18 Chacon AC, Melucci AD, Qin SS, Prieto PA. Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma. Int J Mol Sci 2021;22:3228. [PMID: 33810078 DOI: 10.3390/ijms22063228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Vergani E, Dugo M, Cossa M, Frigerio S, Di Guardo L, Gallino G, Mattavelli I, Vergani B, Lalli L, Tamborini E, Valeri B, Gargiuli C, Shahaj E, Ferrarini M, Ferrero E, Gomez Lira M, Huber V, Vecchio MD, Sensi M, Leone BE, Santinami M, Rivoltini L, Rodolfo M, Vallacchi V. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators. Cell Commun Signal 2020;18:156. [PMID: 32967672 DOI: 10.1186/s12964-020-00601-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]